Premium
Chalcone hybrids as potential anticancer agents: Current development, mechanism of action, and structure‐activity relationship
Author(s) -
Gao Feng,
Huang Gang,
Xiao Jiaqi
Publication year - 2020
Publication title -
medicinal research reviews
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.868
H-Index - 130
eISSN - 1098-1128
pISSN - 0198-6325
DOI - 10.1002/med.21698
Subject(s) - chalcone , pharmacophore , mechanism of action , drug , pharmacology , anticancer drug , mechanism (biology) , drug resistance , computational biology , chemistry , in vitro , biology , bioinformatics , biochemistry , stereochemistry , genetics , philosophy , epistemology
The continuous emergency of drug‐resistant cancers and the low specificity of anticancer agents have been the major challenges in the control and treatment of cancer, making an urgent need to develop novel anticancer agents with high efficacy. Chalcones, precursors of flavonoids and isoflavonoids, exhibit structural heterogeneity and can act on various drug targets. Chalcones which demonstrated potential in vitro and in vivo activity against both drug‐susceptible and drug‐resistant cancers, are useful templates for the development of novel anticancer agents. Hybridization of chalcone moiety with other anticancer pharmacophores could provide the hybrids which have the potential to overcome drug resistance and improve the specificity, so it represents a promising strategy to develop novel anticancer agents. This review emphasizes the development, the mechanisms of action as well as structure‐activity relationships of chalcone hybrids with potential therapeutic application for many cancers in recent 10 years.